Skip to main content

Table 1 Demographics by intervention arm

From: A phase II dose evaluation pilot feasibility randomized controlled trial of cholecalciferol in critically ill children with vitamin D deficiency (VITdAL-PICU study)

Patient Characteristic

Treatment (n = 40)

Placebo (n = 19)

Age (months), median (IQR)

13.4 (2.1, 86.8)

11.8 (2.1, 87.9)

Weight (kg), median (IQR)

12.4 (5.0, 25.0)

7.5 (4.8, 28.1)

Sex, frequency (%)

Female

16 (40.0)

9 (47.4)

Male

24 (60.0)

10 (52.6)

Recruitment country, frequency (%)

Canada

33 (82.5)

16 (84.2)

Other country

7 (17.5)

3 (15.8)

ICU type, frequency (%)

NICU

3 (7.5)

2 (10.5)

PICU

37 (92.5)

17 (89.5)

Admission season, frequency (%)

Fall

8 (20.0)

4 (21.1)

Winter

11 (27.5)

7 (36.8)

Spring

9 (22.5)

4 (21.1)

Summer

12 (30.0)

4 (21.1)

Ethnicity,frequency (%)

Caucasian

17 (42.5)

11 (57.9)

Aboriginal, Inuit

3 (7.5)

1 (5.3)

Black

2 (5.0)

2 (10.5)

Other/Unknown/Missing

18 (45.0)

5 (26.3)

Chronic conditiona, frequency (%)

15 (37.5)

9 (47.4)

Endocrine condition

1 (6.7)

1 (11.1)

Renal disease

2 (13.3)

0 (0.0)

GI disease

1 (6.7)

1 (11.1)

Malabsorption

1 (6.7)

0 (0.0)

Other

14 (93.3)

7 (77.8)

Admitting diagnosis, frequency (%)

Medical

31 (77.5)

12 (63.2)

Cardiac surgery

6 (15.0)

6 (31.6)

General surgery

2 (5.0)

1 (5.3)

Trauma

1 (2.5)

0 (0.0)

Cardiac, non-surgical

0 (0.0)

0 (0.0)

PRISM III score, median (IQR)

7.0 (4.0, 12.0)

8.0 (2.5, 11.5)

Mechanical ventilation required, frequency (%)

32 (80.0)

16 (84.2)

Received catecholamines, frequency (%)

20 (50.0)

9 (47.4)

  1. aPlease note that conditions are not mutually exclusive and thus will not total 100%
  2. IQR Interquartile range, ICU Intensive care unit, PICU Pediatric intensive care unit, NICU Neonatal intenstive care unit, GI Gastrointestinal, PRISMPediatric Risk of Mortality